Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
Status:
Not yet recruiting
Trial end date:
2023-06-27
Target enrollment:
Participant gender:
Summary
This is a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and
safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18
or older with CRSwNP that is not adequately controlled with existing therapies.
Duration of study period (per participant):
- Screening Period (2 to 4 weeks)
- Intervention Period (up to 52 weeks±3 days)